TDCPP (Tris(1,3-dichloroisopropyl)phosphate)
(Synonyms: 磷酸三(1,3-二氯异丙基)酯,Tris(1,3-dichloroisopropyl)phosphate) 目录号 : GC34128
TDCPP（三（1,3-二氯异丙基）磷酸酯）是磷酸三（2,3-二溴丙基）酯（Tris）的氯化类似物，它是环境中检测到最多的有机磷阻燃剂（OPFR）之一。
Cas No.:13674-87-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TDCPP is a chlorinated analog of tris(2,3-dibromopropyl)phosphate (Tris) which is one of the most detected organophosphorus flame retardants (OPFRs) in the environment.
Exposure to TDCPP does not significantly affect cell viability until at concentration >68 μg/mL. HCECs show a 16% cell viability loss after exposing to 136 μg/mL TDCPP. Moreover, TDCPP induces a sharp decrease in viable cells (87%) after exposing to ≥272 μg/mL TDCPP. Based on cell viability, the LC50 value for TDCPP is 202 μg/mL using a nonlinear regression. Compare to controls, TDCPP-exposed cells exhibit a concentration-dependent increase in apoptosis. Anti-apoptotic Bcl-2 protein expression is increased to 1.4 fold after exposing to 2 μg/mL TDCPP, 1.2-folds at 20 μg/mL but dynamically decreased to 0.4 fold at 200 μg/mL compare to control. The caspase-3 activity is increased to 2.1 folds of the control at 200 μg/mL TDCPP[1]. TDCPP inhibits cell growth at lower concentrations (IC50 of 27 μM), while cell viability and toxicity are affected at higher concentrations (IC50 of 171 μM and 168 μM, respectively)[2].
[1]. Xiang P, et al. Effects of organophosphorus flame retardant TDCPP on normal human corneal epithelial cells: Implications for human health. Environ Pollut. 2017 Nov;230:22-30. [2]. Killilea DW, et al. Flame retardant tris(1,3-dichloro-2-propyl)phosphate (TDCPP) toxicity is attenuated by N-acetylcysteine in human kidney cells. Toxicol Rep. 2017 May 17;4:260-264.
|
Kinase experiment: |
The cellular ATP contents are determined in HCECs grown in DMEM containing 0, 2, 20, or 200 μg/mL TDCPP using a luciferase-based ATP assay kit according to the manufacturer's guideline. Briefly, after 24 h exposure, HCECs are lysed with lysis buffer. Lysates are then centrifuged at 12,000 g at 4°C for 5 min. Then, 100 μL of supernatant is mixed with 100 μL ATP detection working dilution. Luminance is examined by an fluorescence microplate reader[1]. |
|
Cell experiment: |
To examine the effects of TDCPP on cell viability, HCECs are planted into 96-well plate (100 μL/well) at density of 1×105 cells/mL overnight. Then, the medium is changed into fresh medium containing 0.034, 0.34, 3.4, 34, 68, 136, 272, or 340 μg/mL of TDCPP and solvent vehicle (0.1%, v/v) and incubated for 24 h. Cell viability is detected using CCK-8 cell viability assay kit according to the manufacturer's instructions. After exposure, cellular morphology is observed and recorded by an inverted microscopy[1]. |
|
References: [1]. Xiang P, et al. Effects of organophosphorus flame retardant TDCPP on normal human corneal epithelial cells: Implications for human health. Environ Pollut. 2017 Nov;230:22-30. |
|
| Cas No. | 13674-87-8 | SDF | |
| 别名 | 磷酸三(1,3-二氯异丙基)酯,Tris(1,3-dichloroisopropyl)phosphate | ||
| Canonical SMILES | O=P(OC(CCl)CCl)(OC(CCl)CCl)OC(CCl)CCl | ||
| 分子式 | C9H15Cl6O4P | 分子量 | 430.9 |
| 溶解度 | DMSO : ≥ 62.5 mg/mL (145.05 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3207 mL | 11.6036 mL | 23.2072 mL |
| 5 mM | 0.4641 mL | 2.3207 mL | 4.6414 mL |
| 10 mM | 0.2321 mL | 1.1604 mL | 2.3207 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet